T 2643/16 (Sofosbuvir/GILEAD) of 03.06.2024
- European Case Law Identifier
- ECLI:EP:BA:2024:T264316.20240603
- Date of decision
- 3 June 2024
- Case number
- T 2643/16
- Petition for review of
- -
- Application number
- 08732818.3
- IPC class
- A61K 31/7064A61K 31/7076
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- T 2643/16 Sofosbuvir/GILEAD 2023-02-16
- Abstracts for this decision
- Abstract on EPC2000 Art 087(1)
- Application title
- NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS
- Applicant name
- Gilead Pharmasset LLC
- Opponent name
- MEDECINS DU MONDE
Fleischer, Holm Herbert
ELLIS IP LTD
Pharmaceutical Works POLPHARMA
Generics [UK] Ltd (trading as Mylan)
Teva Pharmaceutical Industries Ltd.
I P S Intellectual Property Services
STADA Arzneimittel AG
ZBM Patents - Zea, Barlocci & Markvardsen
Actavis Group PTC ehf - Board
- 3.3.07
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 83 1973European Patent Convention Art 87 1973
- Keywords
- Priority - (yes)
Sufficiency of disclosure - (yes) - Catchword
- -
Order
For these reasons it is decided that:
The appeals are dismissed.